EJC Paediatric Oncology,
Journal Year:
2024,
Volume and Issue:
3, P. 100160 - 100160
Published: March 17, 2024
Despite
intensive
therapies,
pediatric
patients
with
relapsed
or
refractory
solid
tumors
have
poor
outcomes
and
need
novel
treatments.
Immune
therapies
offer
an
alternative
to
conventional
treatment
options
but
require
the
identification
of
differentially
expressed
antigens
direct
antitumor
activity
sites
disease.
B7-H3
(CD276)
is
immune
regulatory
protein
that
in
a
range
malignancies
has
limited
expression
normal
tissues.
highly
including
osteosarcoma,
rhabdomyosarcoma,
Ewing
sarcoma,
Wilms
tumor,
neuroblastoma,
many
rare
tumors.
In
this
article
we
review
B7-H3-targeted
chimeric
antigen
receptor
(B7-H3-CAR)
T
cell
for
tumors,
reporting
preclinical
development
strategies
outlining
landscape
active
clinical
trials.
We
identify
challenges
success
CAR
therapy
localizing
penetrating
tumor
sites,
evading
hostile
microenvironment,
supporting
expansion
persistence,
avoiding
intrinsic
resistance.
highlight
overcome
these
enhance
effect
B7-H3-CAR
cells,
advanced
design
incorporation
combination
therapies.
Frontiers in Immunology,
Journal Year:
2023,
Volume and Issue:
14
Published: Sept. 7, 2023
Gliomas
are
the
most
prevalent
primary
malignant
brain
tumors
worldwide,
with
glioblastoma
(GBM)
being
common
and
aggressive
type.
Despite
two
decades
of
relentless
pursuit
in
exploring
novel
therapeutic
approaches
for
GBM,
there
is
limited
progress
improving
patients’
survival
outcomes.
Numerous
obstacles
impede
effective
treatment
including
immunosuppressive
tumor
microenvironment
(TME),
blood-brain
barrier,
extensive
heterogeneity.
these
challenges,
immunotherapies
emerging
as
a
promising
avenue
that
may
offer
new
hope
gliomas.
There
four
main
types
gliomas,
immune
checkpoint
blockades,
chimeric
antigen
receptor
T-cell
therapies,
vaccines,
oncolytic
viruses.
In
addition,
gene
therapy,
bispecific
antibody
combine
therapy
also
briefly
introduced
this
review.
The
significant
role
TME
process
has
been
emphasized
many
studies.
Although
immunotherapy
enormous
effort
required
to
overcome
existing
barriers
its
success.
Owing
rapid
development
increasing
attention
paid
article
aims
review
recent
advances
Signal Transduction and Targeted Therapy,
Journal Year:
2024,
Volume and Issue:
9(1)
Published: Oct. 18, 2024
Immunotherapy
has
made
significant
strides
in
cancer
treatment,
particularly
through
immune
checkpoint
blockade
(ICB),
which
shown
notable
clinical
benefits
across
various
tumor
types.
Despite
the
transformative
impact
of
ICB
treatment
therapy,
only
a
minority
patients
exhibit
positive
response
to
it.
In
with
solid
tumors,
those
who
respond
well
typically
demonstrate
an
active
profile
referred
as
"hot"
(immune-inflamed)
phenotype.
On
other
hand,
non-responsive
may
distinct
"cold"
(immune-desert)
phenotype,
differing
from
features
tumors.
Additionally,
there
is
more
nuanced
"excluded"
positioned
between
and
categories,
known
type.
Effective
differentiation
understanding
intrinsic
factors,
characteristics,
TME,
external
factors
are
critical
for
predicting
results.
It
widely
accepted
that
therapy
exerts
profound
effect
on
limited
efficacy
against
or
"altered"
necessitating
combinations
therapeutic
modalities
enhance
cell
infiltration
into
tissue
convert
tumors
ones.
Therefore,
aligning
traits
this
review
systematically
delineates
respective
influencing
extensively
discusses
varied
approaches
drug
targets
based
assess
efficacy.
Frontiers in Immunology,
Journal Year:
2024,
Volume and Issue:
15
Published: Jan. 29, 2024
Cancer,
a
disease
that
modern
medicine
has
not
fully
understood
and
conquered,
with
its
high
incidence
mortality,
deprives
countless
patients
of
health
even
life.
According
to
global
cancer
statistics,
there
were
an
estimated
19.3
million
new
cases
nearly
10
deaths
in
2020,
the
age-standardized
mortality
rates
201.0
100.7
per
100,000,
respectively.
Although
remarkable
advancements
have
been
made
therapeutic
strategies
recently,
overall
prognosis
remains
optimistic.
Consequently,
are
still
many
severe
challenges
be
faced
difficult
problems
solved
therapy
today.
Epigallocatechin
gallate
(EGCG),
natural
polyphenol
extracted
from
tea
leaves,
received
much
attention
for
antitumor
effects.
Accumulating
investigations
confirmed
EGCG
can
inhibit
tumorigenesis
progression
by
triggering
apoptosis,
suppressing
proliferation,
invasion,
migration,
altering
tumor
epigenetic
modification,
overcoming
chemotherapy
resistance.
Nevertheless,
regulatory
roles
biomolecular
mechanisms
immune
microenvironment,
metabolic
immunotherapy
remain
obscure.
In
this
article,
we
summarized
most
recent
updates
about
effects
on
microenvironment
(TME),
reprogramming,
anti-cancer
immunotherapy.
The
results
demonstrated
promote
response
cytotoxic
lymphocytes
dendritic
cells
(DCs),
attenuate
immunosuppression
myeloid-derived
suppressor
(MDSCs)
T
(Tregs),
tumor-promoting
functions
tumor-associated
macrophages
(TAMs),
neutrophils
(TANs),
various
stromal
including
cancer-associated
fibroblasts
(CAFs),
endothelial
(ECs),
stellate
cells,
mesenchymal
stem/stromal
(MSCs).
Additionally,
suppress
multiple
reprogramming
pathways,
glucose
uptake,
aerobic
glycolysis,
glutamine
metabolism,
fatty
acid
anabolism,
nucleotide
synthesis.
Finally,
EGCG,
as
immunomodulator
checkpoint
blockade,
enhance
immunotherapeutic
efficacy
may
promising
candidate
conclusion,
plays
versatile
TME
which
provides
novel
insights
combined
Molecular Cancer,
Journal Year:
2024,
Volume and Issue:
23(1)
Published: Nov. 15, 2024
Normal
life
requires
cell
division
to
produce
new
cells,
but
death
is
necessary
maintain
balance.
Dysregulation
of
can
lead
the
survival
and
proliferation
abnormal
promoting
tumor
development.
Unlike
apoptosis,
necrosis,
autophagy,
newly
recognized
forms
regulated
(RCD)
cuproptosis,
ferroptosis,
PANoptosis
provide
novel
therapeutic
strategies
for
treatment.
Increasing
research
indicates
that
immune
cells
mediated
by
these
discovered
regulate
microenvironment
(TME)
influence
effectiveness
immunotherapy.
This
review
primarily
elucidates
molecular
mechanisms
their
complex
effects
on
TME.
also
summarizes
exploration
nanoparticle
applications
in
therapy
based
vivo
vitro
evidence
derived
from
induction
or
inhibition
RCD
pathways.
Angewandte Chemie International Edition,
Journal Year:
2024,
Volume and Issue:
63(22)
Published: March 29, 2024
The
immune
checkpoint
blockade
strategy
has
improved
the
survival
rate
of
late-stage
lung
cancer
patients.
However,
low
response
limits
immunotherapy
efficiency.
Here,
we
report
a
ROS-responsive
Fe
Pharmaceutics,
Journal Year:
2025,
Volume and Issue:
17(2), P. 142 - 142
Published: Jan. 21, 2025
Glioblastoma’s
(GB)
complex
tumor
microenvironment
(TME)
promotes
its
progression
and
resistance
to
therapy.
A
critical
component
of
TME
is
the
extracellular
matrix
(ECM),
which
plays
a
pivotal
role
in
promoting
tumor’s
invasive
behavior
aggressiveness.
Nanotechnology
holds
significant
promise
for
GB
treatment,
with
potential
address
challenges
posed
by
both
blood-brain
barrier
ECM.
By
enabling
targeted
delivery
therapeutic
diagnostic
agents,
nanotechnology
offers
prospect
improving
treatment
efficacy
accuracy
at
site.
This
review
provides
comprehensive
exploration
GB,
including
epidemiology,
classification,
current
strategies,
alongside
intricacies
TME.
It
highlights
nanotechnology-based
focusing
on
nanoparticle
formulations
such
as
liposomes,
polymeric
nanoparticles,
gold
have
shown
Furthermore,
it
explores
how
different
emerging
strategies
modulate
ECM
overcome
high
density,
restricts
drug
distribution
within
tumors.
emphasizing
intersection
ECM,
this
underscores
an
innovative
approach
advancing
treatment.
addresses
limitations
therapies,
identifies
new
research
avenues,
emphasizes
improve
patient
outcomes.
